CRB Inverbio takes 50% stake in Mecwins

The fresh capital will be used to expand Mecwin's team and development facilities and to refine the company's technology platform.

Funding was taken from CRB's second biomedicine-focused fund and marks the VC's seventh investment from the vehicle in a Spanish company. CRB has completed one investment this year: an injection of €3m into wearable medical technology company Nuubo in May 2014 alongside Caixa.

CRB Bio II is a €30m vehicle that held its first close in May 2012 after launching in October 2010, according to unquote" data. LPs include the European Investment Fund, the Spanish state's financial agency ICO – investing through Axis – and Enisa. The CRB management also invested capital equal to 5% of the vehicle. The fund will invest in 10-12 SMEs in the biomedical sector over a period of eight years.

Company
Founded in 2009 in Santiago de Compostela as a spinout of the bio-nanomechanical investigation group of the Microelectronic Institute (CSIS) in Madrid, the company develops nanomechanical sensors for the detection of DNA sequences and proteins, the classification of bacteria and other medical applications.

Its main facilities are located in the Tres Cantos Scientific Park in Madrid. The main use of the technology is for the medical diagnosis of personalised medicine. Its platform for biosensing is currently in the commercialisation phase.

People
Oscar Ahumada is executive director at Mecwins. Enrique Castellón is president of CRB.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe
• Healthcare
• Early-stage
• Spain